1) ductal carcinoma in situ with microinvasion
导管内癌微浸润
2) DCIS
导管内癌(或伴早期浸润)
3) infiltrating ductal carcinoma
浸润性导管癌
1.
Differential proteomic analysis in stage Ⅱ breast infiltrating ductal carcinoma tissue with negative estrogen receptor
ER~- Ⅱ期乳腺浸润性导管癌的差异表达蛋白质分析
2.
Objective:The aim of this study was to investigate the X-ray features of infiltrating ductal carcinoma and to analysis its pathological basis and to rise the level of the preoperative diagnostic accuracy.
目的:研究浸润性导管癌的X线表现,分析其病理学基础,以提高乳腺癌手术前的诊断水平。
3.
Purpose To detect the expression of matrix metalloproteinase-26(MMP-26) in human benign and malignant breast tissues,to evaluate the relationship of MMP-26 expression in infiltrating ductal carcinoma(IDC)with clinicopathological parameters and its potential value in tumor progression and to explore the correlation of MMP-26 with estrogen receptor(ER).
方法应用免疫组化SP法,检测MMP-26蛋白在正常乳腺组织、乳腺增生症、原位癌和乳腺浸润性导管癌(IDC)中的表达,以及ER在IDC中的表达并进行评分,结果用INSTAT统计软件分析。
4) Invasive ductal carcinoma
浸润性导管癌
1.
Expression of Ezrin and Galectin-3 and their clinicopathological significance in breast invasive ductal carcinoma;
乳腺浸润性导管癌中Ezrin、Galectin-3的表达及临床病理意义
2.
Reproducibility in evaluating immunohistochemical results of HER2 expression in breast invasive ductal carcinoma;
乳腺浸润性导管癌HER2免疫组化检测结果判定的重复性研究
3.
Expression and clinicopathologic significance of Ki-67 in breast invasive ductal carcinoma;
乳腺浸润性导管癌Ki-67表达及其临床病理学意义
5) IDC
浸润性导管癌
1.
Objective To study the relationship between the expression of p57KIP2 and clinicopathological characteristics in invasive duct carcinoma(IDC).
目的研究p57KIP2在乳腺浸润性导管癌(invasive duct carcinoma,IDC)中的表达及与临床病理特征的关系。
2.
Objective To study the expression cyclinD1,and p57KIP2in invasive duct carcinoma (IDC) and their clinical significances.
目的研究cyclinD1、p57KIP2在乳腺浸润性导管癌(IDC)中的表达及意义。
3.
[Background and Objective] Breast cancer is one of the most common malignant tumors in women with 75% of which exhibiting invasive ductal carcinoma (IDC) when diagnosed.
乳腺癌的75%表现为浸润性导管癌,目前按病理学进程大致将其发生划分为正常乳腺上皮→增生→不典型增生→原位癌→浸润性癌→转移性癌等几个阶段,但其过程中确切分子机制至今仍不详。
6) invasive ductal carcinoma
乳腺导管浸润癌
1.
Expressions of Bcl-2 and PCNA in invasive ductal carcinoma of breast and their clinical significance;
凋亡抑制基因Bcl-2和增殖细胞核抗原在乳腺导管浸润癌中的表达及意义
补充资料：早期浸润癌
早期浸润癌
从原位癌发展到浸润癌的过程较缓慢，浸润时大多在一局部突破基底膜，浸润于间质。有不少学者研究认为浸润在3～5mm以内者，为早期浸润癌。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条